Company Information & Drug Savings for Argenx Medications
Argenx is a global immunology company developing antibody-based medicines for autoimmune diseases and cancer. Based in Boston, Massachusetts, the company developed VYVGART (efgartigimod), the first FDA-approved FcRn blocker for generalized myasthenia gravis (gMG). Argenx’s innovative ENHANZE technology platform creates next-generation treatments for immune-mediated disorders including chronic inflammatory demyelinating polyneuropathy (CIDP), pemphigus, and other severe autoimmune conditions.
How to Contact Argenx
Phone
1-857-209-5917Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
